ATR and neoplasm: Patient 212, a pre-menopausal woman with a triple-negative subtype diagnosed at stage 2 and treated with EC, exhibited strong positive immune reactivity for both phosphorylated ATR and ATM in the tumor (Figure 7A,B), correlating with a DFS of 184 months.